InsidersTradesSigma
Explore the full insider trade history of Avalanche Biotechnologies, Inc., a publicly traded company based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 1 February 2016 (Attribution). Among the most active insiders: Wachter Paul. All data is free.
Analysts rate Avalanche Biotechnologies, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
2 of 2 declarations
Avalanche Biotechnologies, Inc. is a biopharmaceutical company focused on developing gene therapies for treating eye diseases and other conditions. It is listed on the XNAS market.